Biomarkers /
GNA11
Overview
GNA11 (guanine nucleotide binding protein (G protein), alpha 11 (Gq class)) is a gene that encodes the guanine nucleotide-binding protein subunit alpha-11, a subunit of one of the heterotrimeric guanine nucleotide binding proteins (G proteins). Oncogenic mutations result in a constitutively active Gα subunit (PMID: 1328859; PMID: 2549426). Receptor activation causes the dissociation of the Gα subunit from Gßγ. Both Gα and Gßγ can then activate downstream cellular signaling pathways (PMID: 1328859; PMID: 2549426).
GNA11 is altered in 0.89% of all cancers with uveal melanoma, lung adenocarcinoma, colon adenocarcinoma, breast invasive ductal carcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in GNA11 are GNA11 Mutation (0.64%), GNA11 Exon 5 Mutation (0.26%), GNA11 Loss (0.25%), GNA11 Codon 209 Missense (0.17%), and GNA11 Q209L (0.16%) [3].
Clinical Trials
Significance of GNA11 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.